Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that DSM Biomedical obtained an exclusive world-wide license for a unique drug & biologics delivery system developed by MediVas LLC. MediVas' technology for the delivery of biologics and drugs is based on a next generation set of polymers exclusively licensed from Cornell University. The polymers are biodegradable, biocompatible and bioabsorbable. Furthermore they are non-inflammatory and allow greater control over the rate and duration of release of their therapeutic payload. "Through this deal we bring in the first fully developed biodegradable polymer into DSM's Biomedical portfolio, which significantly enhances our materials competences," says Steve Hartig, President of DSM Biomedical.
The license for the unique drug & biologics delivery system will be integrated into DSM's Trancerta® Drug Delivery platform, this will open up a broad range of opportunities for next generation drug delivery. DSM's activities in this field are an illustration of the way DSM is leveraging its competences in Materials Sciences into Life Sciences applications. The technology can be used with a diverse group of drug candidates, from small molecule drugs to large molecules like proteins, peptides and nucleic acids, thus expanding the possible application areas of DSM's Trancerta® platform. The license DSM obtained applies for the development of drug delivery systems aimed at treating ophthalmic, cardiovascular, musculoskeletal diseases and at providing general pain relief.